Evidence map›Paper›PMID 32648681›Full record

ArticleAdvanced biosystems2019

Osterix-mCherry Expression Allows for Early Bone Detection in a Calvarial Defect Model.

Sara E Strecker, Shimon Unterman, Lyndon F Charles, Dmitry Pivovarchick, Peter F Maye, Elazer R Edelman, Natalie Artzi

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced biosystems, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Sara E StreckerMassachusetts Institute of Technology, Institute for Medical Engineering and Science, 45 Carleton Street, E25-438, Cambridge, MA, 02139, USA.ORCID 0000-0001-6425-2184
Shimon UntermanMassachusetts Institute of Technology, Institute for Medical Engineering and Science, 45 Carleton Street, E25-438, Cambridge, MA, 02139, USA.
Lyndon F CharlesMassachusetts Institute of Technology, Institute for Medical Engineering and Science, 45 Carleton Street, E25-438, Cambridge, MA, 02139, USA.
Dmitry PivovarchickDepartment of Reconstructive Sciences, University of Connecticut, Farmington, CT, 06032, USA.
Peter F MayeCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Elazer R EdelmanMassachusetts Institute of Technology, Institute for Medical Engineering and Science, 45 Carleton Street, E25-438, Cambridge, MA, 02139, USA.
Natalie ArtziMassachusetts Institute of Technology, Institute for Medical Engineering and Science, 45 Carleton Street, E25-438, Cambridge, MA, 02139, USA.
Massachusetts Institute of Technology · USBrigham and Women's Hospital · USBraude College of Engineering Karmiel · ILUniversity of Connecticut · US

Funding

Vascular Drug Delivery - Supplement for EquipmentR01GM049039 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI EDELMAN, ELAZER R · 1994 to 2019
$8.9M
Skeletal Phenotyping of Heterozygotes from IMPC Embryonic Lethal LinesR01HD098636 · NICHD · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI MAYE, PETER, ROWE, DAVID W. · 2019 to 2023
$2.8M
NICHD NIH HHS R01 HD098636NIGMS NIH HHS R01 GM049039NIH HHS R01 GM 49039
6 · The paper itself

Abstract

The process of new bone formation following trauma requires the temporal recruitment of cells to the site, including mesenchymal stem cells, preosteoblasts, and osteoblasts, the latter of which deposit minerals. Hence, bone repair, a process that is assessed by the extent of mineralization within the defect, can take months before it is possible to determine if a treatment is successful. Here, a fluorescently tagged Osterix, an early key gene in the bone formation cascade, is used as a predictive measure of bone formation. Using a calvarial defect model in mice, the ability to noninvasively track the Osterix transcription factor in an Osterix-mCherry mouse model is evaluated as a measure for bone formation following treatment with recombinant human Bone-Morphogenetic-Protein 2 (rhBMP-2). Two distinct delivery materials are utilized, an injectable nanocomposite hydrogel and a collagen sponge, that afford distinct release kinetics and it is found that cherry-fluorescent protein can be detected as early as 2 weeks following treatment. Osterix intensity correlates with subsequent bone formation and hence can serve as a rapid screening tool for osteogenic drugs or for the evaluation and optimization of delivery platforms.

Indexed as

AnimalsBone Morphogenetic Protein 2Cells, CulturedLuminescent ProteinsMesenchymal Stem CellsMiceOsteoblastsOsteogenesisRecombinant Fusion ProteinsRecombinant ProteinsRed Fluorescent ProteinRegenerationSkullSp7 Transcription FactorTissue ScaffoldsTransforming Growth Factor betaBone Morphogenetic Protein 2Luminescent ProteinsRecombinant Fusion Proteinsrecombinant human bone morphogenetic protein-2Recombinant ProteinsRed Fluorescent ProteinSp7 protein, mouseSp7 Transcription FactorTransforming Growth Factor betaBMP-2bone regenerationimagingnanocompositeOsterixscaffold

Identifiers

PMID32648681
PMCPMC7393777
OpenAlexW2988127120

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.